leading glp-1 medications 2025 Beyond GLP-1: the next wave of weight-loss medication innovation GLP-1 Drugs: 2025 Pulse Survey

If you already have this condition, taking Mounjaro may worsen it

A research study to look into the long-term effect on weight loss of CagriSema in people with obesity (NCT06780449) Summary: This is an ongoing Phase 3 trial (as of current knowledge) designed to evaluate the long-term efficacy and safety of once-weekly CagriSema in people living with obesity

FDA - Certain Bulk Drug Substances for Use in Compounding: Lists BPC-157 with potential safety risks and lack of sufficient information

With multiple options available, each with its unique benefits, dosing schedules and potential side effects, it is essential to engage in a thorough discussion with a healthcare provider

GHRH Analogue Mechanism & UK Status An evidence-based overview of tesamorelin a stabilised GHRH analogue covering how it is studied to work, the clinical data behind its narrow approved use, and its research-use-only status in the UK

Its a direct consequence of the peptide doing its job